PALM BEACH GARDENS, FL--(Marketwire - August 09, 2010) - AccuDial® Pharmaceutical, Inc
., the company that offers the only rotating labeling system for weight-specific dosing, has joined the Consumer Healthcare Products Association (CHPA) Pediatric Cough
/Cold Ingredient Efficacy Research Task Group. AccuDial joins eight of the top over-the-counter (OTC) pediatric manufacturers in this long-term efficacy research program. The task force, which formed in February 2010, also includes Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Consumer Health, Inc., McNeil Consumer Healthcare Division of McNeil-PPC, Inc., Perrigo Company, The Procter & Gamble Company, Reckitt Benckiser Inc., and Wyeth LLC participating through Pfizer Consumer Healthcare.
CHPA is the national trade association representing the leading manufacturers and distributors of OTC medicines in the United States. The association provides leadership and guidance on regulatory and scientific issues to federal, state, and international government agencies. CHPA shares tools and information with partners across the globe to ensure the safe and responsible use of OTC medicines.
CHPA's Voluntary Guidelines are generally consistent with, and in some cases more specific than, the FDA's "Draft Guidance." AccuDial products comply with, and even exceed, the CHPA recommendations. "We are pleased to be a member of this important group," said Robert Terwilliger, CEO of AccuDial Pharmaceutical, Inc. "This research should put to rest any skepticism regarding the benefit and efficacy of pediatric OTC products."
The results of this multiyear program will provide the FDA, physicians, and other health care professionals with pharmacokinetic and clinical data regarding proper dosing for the eight most popular cough and cold active ingredients.
Currently, the Children's AccuDial product line -- from the company's OTC division -- can be found at major pharmaceutical retailers throughout Canada. AccuDial expects that its pain and fever products, utilizing the revolutionary, weight-based dosing system, will be launched in the United States by the end of the year.
About AccuDial Pharmaceutical:
AccuDial Pharmaceutical's patented, weight-based dosing was designed to effectively administer AccuDial's family of children's pain and fever, allergy, and cough and cold medications. A parent simply rotates the label until their child's weight appears in the viewing window and the correct dose is shown below the weight. A dosing spoon is included in each package so parents can easily measure and administer the medication. Children's AccuDial is the only medication that provides weight-specific dosing using a rotating label. For more information, contact AccuDial Pharmaceutical, Inc. at accuratedose.com.
The information contained in this press release includes "forward-looking statements." All statements other than statements of historical facts included in this press release, including the Company's prospects, plans, financial position, and business strategy, may constitute forward-looking statements. These statements are based on the beliefs and assumptions of our management, and on the information currently available to our management at the time of such statements. Forward-looking statements generally can be identified by the words "believes," "expects," "anticipates," "intends," "plans," "estimates," or similar expressions that indicate future events and trends. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company can give no assurance that these expectations will prove to be correct, and the Company's actual results may differ significantly from the results discussed in these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events, or otherwise.